Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 22;381(8):699-701.
doi: 10.1056/NEJMp1904714.

Prescription Drug Monitoring Programs - Friend or Folly in Addressing the Opioid-Overdose Crisis?

Rebecca L Haffajee  1
Affiliations

Prescription Drug Monitoring Programs - Friend or Folly in Addressing the Opioid-Overdose Crisis?

Rebecca L Haffajee. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure.
Figure.. Prescription Drug Monitoring Program Feature Implementation, 2018–2017
States with Selected Prescription Drug Monitoring Program Features, 2008–2017. * *Data are from the author’s primary legal research and the Prescription Drug Abuse Policy System. “Housed in a health agency” means the agency in charge of PDMP operation is a state department of health, board of pharmacy, or professional licensing body. “Prescriber registration requirement” means the PDMP automatically enrolls prescribers or there is a requirement that prescribers enroll in (i.e., obtain login information for) the PDMP. “Prescriber use requirement” is a requirement that prescribers access PDMP data under specified clinical circumstances. “Proactive reporting permitted or required” means the PDMP operating agency is either required or permitted to proactively identify outlier prescribing, dispensing, or purchasing and report findings to professional licensing bodies, prescribers, dispensers, or law-enforcement officials. “Prescriber access” indicates prescribers can access PDMP data when registered with the system.
See this image and copyright information in PMC

References

    1. Haffajee RL, French CA. Provider perceptions of system-level opioid prescribing and addiction treatment policies. Curr Opin Psychol 2019;30:65–73. - PMC - PubMed
    1. Rutkow L, Smith KC, Lai AY, Vernick JS, Davis CS, Alexander GC. Prescription drug monitoring program design and function: A qualitative analysis. Drug Alcohol Depend 2017;180:395–400. - PubMed
    1. Wilson MN, Hayden JA, Rhodes E, Robinson A, Asbridge M. Effectiveness of prescription monitoring programs in reducing opioid prescribing, dispensing, and use outcomes: a systematic review. J Pain 2019. doi: 10.1016/j.jpain.2019.04.007.4. - DOI - PubMed
    1. Mauri AI, Townsend TN, Haffajee RL. The association of state opioid misuse prevention policies with patient and provider related outcomes: a scoping review. Millbank Q (forthcoming 2019). - PMC - PubMed
    1. Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health 2018;10:1394–1400. - PMC - PubMed

MeSH terms

Substances